Oropharyngeal Squamous Cell Carcinoma Clinical Trials

67 clinical trials for Oropharyngeal Squamous Cell Carcinoma across international registries, including 24 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer — RECRUITING · PHASE2
• Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma — RECRUITING · PHASE2
• Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation — RECRUITING · NA
• The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan — RECRUITING
• Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) — RECRUITING · PHASE2
• Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer — RECRUITING · PHASE2
• People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity — RECRUITING
• Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma — RECRUITING · PHASE2
• Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery — RECRUITING · PHASE1
• Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer — RECRUITING · PHASE2
• Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC — RECRUITING
• Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma — RECRUITING · PHASE2
• Oropharynx (OPX) Biomarker Trial — RECRUITING
• Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer — RECRUITING · PHASE2
• The Role of Circulating Tumour DNA in Head and Neck Cancer — RECRUITING
• Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma. — RECRUITING · PHASE2
• Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx — RECRUITING
• Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study. — RECRUITING · PHASE3
• Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer — RECRUITING · PHASE1
• A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC — RECRUITING
• Validity of Viome's Oral/throat Cancer Test — RECRUITING
• Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer — RECRUITING · PHASE1
• Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) — RECRUITING · PHASE2
• Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma — RECRUITING · PHASE2
• Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer — NOT_YET_RECRUITING · PHASE1
• A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED) — NOT_YET_RECRUITING · PHASE2
• Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110) — ACTIVE_NOT_RECRUITING · PHASE2
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin — COMPLETED · PHASE2
• SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer — NOT_YET_RECRUITING · NA
• EORTC 1740: Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC) — TERMINATED · PHASE2
• De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers — NOT_YET_RECRUITING · NA
• Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Post-treatment Surveillance in HPV+ Oropharyngeal SCC — ACTIVE_NOT_RECRUITING
• Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) — NOT_YET_RECRUITING · PHASE2
• Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation — NOT_YET_RECRUITING · PHASE2
• Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC — ACTIVE_NOT_RECRUITING · PHASE2
• Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma — NOT_YET_RECRUITING · PHASE1
• Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal Cancer — ACTIVE_NOT_RECRUITING · NA
• Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) — TERMINATED · NA
• Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples? — ACTIVE_NOT_RECRUITING
• Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma — COMPLETED
• Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial. — COMPLETED · PHASE2
• Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer — WITHDRAWN
• Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma — NOT_YET_RECRUITING · PHASE2
• Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) — ACTIVE_NOT_RECRUITING · PHASE2
• Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma — COMPLETED · PHASE1
• Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer — NOT_YET_RECRUITING · PHASE2
• Phase II Clinical Trial of De-Intensified Therapy in Human Papilloma Virus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma — NOT_YET_RECRUITING · PHASE2
• Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma — NOT_YET_RECRUITING · PHASE2

Refine this search